Cadila Health Care v. Cadila Pharmaceuticals — Trademark Case Law

Citation & Court

Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., (2001) 5 SCC 73; also reported at 2001 (2) PTC 541 (SC), Supreme Court of India, decided 26 March 2001.

The Dispute

Two companies that had once been part of the same group each marketed anti-malarial drugs — one under "Falcigo," the other under "Falcitab." Cadila Health Care alleged the marks were deceptively similar and likely to confuse consumers, with particularly serious consequences given the medicinal nature of the products.

What the Court Held

The Supreme Court laid down a comprehensive framework for assessing deceptive similarity, synthesising decades of Indian and international case law. The factors include: the nature of the marks (word, label, composite); the degree of visual, phonetic, and conceptual similarity; the nature of the goods; the class of purchasers likely to buy them, their education and intelligence, and the care they're likely to exercise; the mode of purchase; and any other relevant surrounding circumstances. The Court emphasised that for medicinal products, a stricter approach is warranted given the risk of confusion translating into a genuine public-health hazard.

How to Use This in Your Reply

This is the framework to open with in almost any opposition, objection reply, or infringement argument turning on similarity — state the factors, then apply each one methodically to your own facts rather than arguing "similarity" in the abstract. If your matter involves pharmaceutical, medicinal, or health-related goods, lean explicitly on the heightened-scrutiny language.

Key takeaway: Deceptive similarity is assessed through a structured, multi-factor test — not a single side-by-side glance — and the standard tightens further for medicinal goods.